Lallemand Pharma Europe and GlaxoSmithKline (GSK) are pleased to announce today the launch of ISMIGEN® in Poland. To support the launch, a medical symposium organized by GSK and dedicated to pneumologists and allergologists was hold today in Warsaw.
ISMIGEN® is a Polyvalent Mechanical Bacterial Lysate (PMBL), also described as oral vaccine. It is produced by Lallemand and recommended in the prevention of acute, sub-acute, recurrent or chronic infections of the upper and lower airways and the bronchopulmonary tree. According to the World Health Organization, respiratory diseases represent today a soaring public health concern around the world.
Warsaw’s symposium was the opportunity to discuss up-to-date data and applications of ISMIGEN® with leading lung experts. Professor M. Cazzola, Chief of the Respiratory Clinical Pharmacology Unit at the University of Rome ‘Tor Vergata’, gave a lecture titled: ‘Bacterial extracts for the prevention of acute exacerbations in chronic obstructive pulmonary disease (COPD)’.
According to the latest World Health Organization (WHO) estimates, 210 million people suffer from COPD in the world, and 3 million people died of COPD in 2005. WHO predicts that COPD will become the third leading cause of mortality worldwide by 2030 (source: WHO, 2007).